Vaccine Induction of Heterologous HIV-1 Neutralizing Antibody B Cell Lineages in Humans

Competing Interest Statement

Conflicts of interest: BFH, SMA, KOS and BK are on patents related to MPER peptide immunogens. CBF is an inventor on patents associated with PEGylated liposome compositions.

Clinical Trial

NCT03934541

Funding Statement

Supported by the HHS, NIH, NIAID, Division of AIDS, Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID) grant AI100645, by the HHS, NIH, NIAID, Division of AIDS Consortia for HIV/AIDS Vaccine Discovery (CHAVD) grant AI144371, by the HHS, NIH, NIAID, Center for HIV Structural Biology grant U54 AI170752, and by a Collaboration for AIDS Vaccine Development (CAVD) grant, OPP1094352/INV-007688, from the Bill & Melinda Gates Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All ethical oversight and monitoring for implementation/running of the trial itself was through HVTN and Sponsor (DAIDS) standard operating procedures. The protocol was reviewed and approved by the institutional review boards at all sites (Brigham and Womens Hospital, Fenway, Columbia University, New York Blood Center, University of Alabama Birmingham, and Fred Hutchinson Cancer Research Center) and written informed consent was obtained from each participant prior to enrollment. When the trial was halted, the event was reviewed by the Protocol Safety Review Team (PSRT), which includes the investigators (protocol Chairs), protocol leadership, and clinical safety specialists, as well as by the HVTN Data and Safety Monitoring Board (DSMB).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes